breast cancer Image Credit source: Getty Images
Breast cancer is one of the most common cancers in women. Surgery, chemotherapy, radiotherapy and hormone therapy are often used in its treatment. Although chemotherapy is effective for many patients, it may be associated with hair loss, fatigue, nausea, and other side effects. In such a situation, doctors are constantly looking for ways to better identify which patients actually need chemotherapy.
An international study named OPTIMA Trial found that with the help of genomic testing, some breast cancer patients may be identified who may not need chemotherapy. This test analyzes the activity of genes present in cancer cells and can help in deciding the treatment according to the patient's condition. According to experts, now cancer treatment is not done only by looking at the type of cancer, but the condition of the patient and the special characteristics of the cancer are also kept in mind. In such a situation, it is important to know how this new genomic test decides whether the patient needs chemotherapy or not and why this test is considered important in the treatment of breast cancer.
The purpose of the genomic test used in the OPTIMA Trial was to analyze the activity of certain genes present in cancer cells. This test helps doctors understand the risk of cancer returning in a patient. The study found that some patients may get good results from hormone therapy alone and may not need more chemotherapy.
Researchers analyzed data from thousands of patients and found that in many low-risk patients, the results remained almost the same even if chemotherapy was not given. This raised the possibility that in future some patients could be saved from unnecessary chemotherapy and its associated side effects. However, the final decision is always taken by the doctor keeping in mind the complete medical condition of the patient.
According to experts, this test is not necessary for every breast cancer patient. There are many types of breast cancer and the condition of every patient is different. Therefore, doctors take this decision after looking at the type of cancer, stage, age of the patient and other medical reports.
In some patients this test can be helpful in planning treatment, while in some cases it is not necessary. Therefore, no patient should assume that this test will be equally useful for everyone. The right decision should be taken only on the basis of expert doctor's advice.
Experts believe that this discovery is an important step towards making breast cancer treatment more accurate and effective. If some patients can be spared from chemotherapy, they will not have to face its side effects and their quality of life can remain better.
Additionally, this approach may help doctors make more scientifically based treatment decisions. This is why the results of the OPTIMA Trial are being seen as an important advancement in the treatment of breast cancer.
